Ardelyx/$ARDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ticker
$ARDX
Sector
Primary listing
Employees
395
Headquarters
Website
Ardelyx Metrics
BasicAdvanced
$1.2B
-
-$0.24
0.68
-
Price and volume
Market cap
$1.2B
Beta
0.68
52-week high
$6.78
52-week low
$3.21
Average daily volume
3.1M
Financial strength
Current ratio
4.302
Quick ratio
3.07
Long term debt to equity
164.27
Total debt to equity
165.117
Interest coverage (TTM)
-1.68%
Profitability
EBITDA (TTM)
-38.094
Gross margin (TTM)
75.74%
Net profit margin (TTM)
-14.60%
Operating margin (TTM)
-10.46%
Effective tax rate (TTM)
-1.69%
Revenue per employee (TTM)
$980,000
Management effectiveness
Return on assets (TTM)
-6.23%
Return on equity (TTM)
-39.36%
Valuation
Price to revenue (TTM)
3.186
Price to book
8.92
Price to tangible book (TTM)
8.92
Price to free cash flow (TTM)
-22.29
Free cash flow yield (TTM)
-4.49%
Free cash flow per share (TTM)
-0.232
Growth
Revenue change (TTM)
83.88%
Earnings per share change (TTM)
-16.07%
3-year revenue growth (CAGR)
320.43%
10-year revenue growth (CAGR)
26.11%
3-year earnings per share growth (CAGR)
-39.90%
10-year earnings per share growth (CAGR)
7.14%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Bulls say / Bears say
In 2024, IBSRELA generated approximately $158 million in U.S. net product sales revenue, and Ardelyx has increased its full-year 2025 IBSRELA guidance to $240–$250 million, reflecting strong commercial performance (FT.com turn9search0).
XPHOZAH delivered approximately $161 million in net product sales revenue during its first full year on the market in 2024 and is projected to reach peak U.S. annual sales of $750 million, showing robust launch momentum (FT.com turn9search0).
As of December 31, 2024, Ardelyx had about $250 million in cash, cash equivalents, and short-term investments, providing a strong financial base for ongoing commercial and pipeline activities (FT.com turn9search0).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ardelyx stock?
Ardelyx (ARDX) has a market cap of $1.2B as of October 09, 2025.
What is the P/E ratio for Ardelyx stock?
The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of October 09, 2025.
Does Ardelyx stock pay dividends?
No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of October 09, 2025.
When is the next Ardelyx dividend payment date?
Ardelyx (ARDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardelyx?
Ardelyx (ARDX) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.